(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

A hypofractionated course of 8 Gy/1 fx radiation therapy in the treatment of bony multiple myeloma metastases is an efficient and effective way to reduce pain and reduce the time from the completion of radiation therapy to the start of chemotherapy in patients with multiple myeloma.

Tijana Skrepnik, MD, April Brookshier, Amit Agarwal, MD, PhD, Krisha J. Howell; University of Arizona

INTRODUCTION: Seventy percent of all patients with multiple myeloma (MM) receive radiation therapy (RT) in the course of their illness. The most standard MM radiation fractionation consists of  ≥ 10 treatments. Randomized phase III trials have proven single-fraction RT to be equivalent to protracted-course RT for bony metastatic sites from breast, prostate, and lung. We reviewed single-dose hypofractionated RT against standard fractionation as administered to MM patients.

METHODS: Diagnosed MM patients treated on our palliative service with RT for bony sites of disease within the past 3 years were reviewed. A total of 21 treatment sites were identified. Sites were treated with a single-dose, hypofractionated RT treatment of 8 Gy in one fraction (fx) or a standard RT course for MM. Data on treatment toxicity (Common Terminology Criteria for Adverse Events version 4.0) of patients while on treatment and at the time of follow-up(s) were collected prospectively. Pain was assessed by the visual analog scale.

RESULTS: We analyzed a total of 17 sites of bony metastases secondary to MM that were treated at our center. Ten sites received hypofractionated RT (8 Gy/1 fx). RT was completed in 16 of 17 sites. Median clinical follow-up was 5.13 months. Median pain scores at the start of RT and time of maximum improvement were 10 and 0, respectively. The response rate was 70.5%, and zero patients had progression of pain. Nine patients had a complete pain response, to a final score of 0, and two patients had a partial response, with a decrease of 2 or more points in their pain. The median time from RT to start of chemotherapy was 1.07 months. A decreased time to start of chemotherapy was evident in the 8 Gy/1 fx subset.

CONCLUSIONS: A hypofractionated course of 8 Gy/1 fx RT in the treatment of bony MM metastases is an efficient and effective way to reduce pain and reduce the time from the completion of RT to the start of chemotherapy in patients with MM. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Related Content